%0 Journal Article
%T Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials
%J -
%D 2019
%R https://doi.org/10.1038/s41391-019-0151-4
%X Up to 90% of men with metastatic castration-resistant prostate cancer (mCRPC) will have a distribution of disease that includes bone metastases demonstrated on a Technetium-99m (99mTc-MDP) bone scan. The Prostate Cancer Working Group 2 and 3 Consensus Criteria standardized the criteria for assessing progression based on the development of new lesions. These criteria have been recognized by regulatory authorities for drug approval. The bone scan index (BSI) is a method to quantitatively measure the burden of bony disease, and can assess both disease progression and regression. The automated BSI (aBSI) is a method of computer analysis to assess BSI, and is being qualified as a clinical trials endpoint
%U https://www.nature.com/articles/s41391-019-0151-4